Abstract
Background: Non-small cell lung cancer is the leading cancer-related cause of death.
Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
Conclusions: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Keywords: Afatinib, EGFR, ELM4-ALK, erlotinib, geftinib, non-small cell lung cancer, osimertinib, patent.
Recent Patents on Anti-Cancer Drug Discovery
Title:EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Ramon Andrade De Mello*, Davi J. J. Liu, Pedro N. Aguiar and Hakaru Tadokoro
Affiliation:
- Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Ala nascente, Edifício 7, 3º Andar, 8005-139, Faro, Portugal.,Portugal
Keywords: Afatinib, EGFR, ELM4-ALK, erlotinib, geftinib, non-small cell lung cancer, osimertinib, patent.
Abstract: Background: Non-small cell lung cancer is the leading cancer-related cause of death.
Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
Conclusions: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Export Options
About this article
Cite this article as:
De Mello Andrade Ramon*, Liu J. J. Davi, Aguiar N. Pedro and Tadokoro Hakaru, EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (4) . https://dx.doi.org/10.2174/1574892811666160803090944
DOI https://dx.doi.org/10.2174/1574892811666160803090944 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendritic Cell Immunotherapy for Malignant Gliomas
Reviews on Recent Clinical Trials The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy
Current Medicinal Chemistry Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Does the Affinity of Cisplatin to B-Vitamins Impair the Therapeutic Effect in the Case of Patients with Lung Cancer-consuming Carrot or Beet Juice?
Anti-Cancer Agents in Medicinal Chemistry Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Natural Products as Anti-Invasive and Anti-Metastatic Agents
Current Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Functional Genome-wide Analysis: a Technical Review, Its Developments and Its Relevance to Cancer Research
Recent Patents on DNA & Gene Sequences The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews The Application of Proteomics for the Early Detection of Lung Cancer
Current Proteomics Analysis of Hypoxiamir-Gene Regulatory Network Identifies Critical MiRNAs Influencing Cell-Cycle Regulation Under Hypoxic Conditions
MicroRNA Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design In Silico Study and Cytotoxicity of the Synthesized Open-chain Analogues of Antimycin A3 Against HEP-2 Laryngeal Cancer Cells
Current Cancer Therapy Reviews Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design Health Beneficial Potential of Pectolinarigenin on Human Diseases: An Updated Review of Medicinal Importance and Pharmacological Activity
The Natural Products Journal Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Medicinal Chemistry Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology